Overview
- Deepinder Goyal announced on X that Temple has acquired Longevous and that founders Dr Robert Mohr and Dr Avi Roy and their team will join Temple full time.
- Dr Robert Mohr will become Temple’s chief medical officer and Dr Avi Roy will serve as head of science, roles that match their clinical and research backgrounds.
- The two founders spent about two months using Temple’s wearable, worked with the in-house team to pressure-test the startup’s Entropy metric, and reviewed the company’s early scientific manuscripts.
- Longevous will continue to operate under Temple and Mohr and Roy will keep personally caring for existing Longevous clients, and Temple did not disclose the purchase price.
- Temple is developing an experimental wearable that monitors cerebral blood flow and other neurological signals, and Goyal has said the company is preparing for a limited launch with pre-orders expected ahead of wider shipping plans later in 2026.